Press "Enter" to skip to content

Lupin gets 4 observations from USFDA after closure of pharmacovigilance inspection

Lupin has received the EIR from the United States Food and Drug Administration (USFDA) for the post-marketing adverse drug experience (PADE) inspection, indicating successful closure of the inspection, the filing added.

Original source:

Also Read:   Delhi govt makes first list of corona warriors for vaccine